HIPAA Compliant
ISO 27001 CertifiedActively Recruiting
Led by Sahlgrenska University Hospital · Updated on 2025-05-14
200
Participants Needed
1
Research Sites
34 weeks
Total Duration
Researchers are investigating how often acute exacerbations of chronic obstructive pulmonary disease AE-COPD trigger a heart condition called Takotsubo-stunning in patients admitted to the hospital. This observational study aims to understand the relationship between AE-COPD and this form of myocardial stunning, which may lead to acute heart failure and affect patient outcomes. The study is conducted at Sahlgrenska University Hospital and focuses on adults hospitalized for AE-COPD. Participants admitted for AE-COPD will be screened using echocardiography to detect signs of heart muscle dysfunction or regional wall motion abnormalities. If signs are found, patients will undergo detailed heart examinations shortly after admission and again 30 days later to see if the heart dysfunction improves, indicating Takotsubo-stunning. Additional data collected will include blood tests, ECG, chest X-rays, and questionnaires about symptoms. Patients who show signs of Takotsubo-stunning will be offered participation in another related study. During the hospital stay, vital signs, complications, and outcomes such as acute heart failure signs and major cardiac events will be monitored. Follow-up data on lung function and exercise capacity will be gathered after hospital care. The study measures include heart function assessment via echocardiography and clinical signs of heart failure during the first days of hospitalization. The total observation includes in-hospital events and a one-year follow-up for mortality and complications.
CONDITIONS
Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital
R
Rickard Zeijlon, M.D. PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sahlgrenska University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 72 hours after hospital admission
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - 30 days
Participants undergo echocardiographic screening to identify signs of regional wall motion abnormality and/or left ventricular dysfunction to detect Takotsubo-stunning. Screening may be repeated after 24 hours if initial screening is negative. If positive, full echocardiographic examinations are performed at baseline, 24 hours, and 30 days.
1 to 3 echocardiographic visits within 30 days
Duration - Average 5 days (duration of hospitalization)
Participants are monitored during hospital stay with blood sampling, ECG, chest x-ray, and registration of vital parameters and clinical signs. In-hospital complications and outcomes are recorded.
Daily assessments during hospital stay
Duration - Up to 1 year
Participants have follow-up assessments after hospital discharge, including re-evaluation of COPD through clinical routine tests such as spirometry, diffusion capacity, lung volumes, 6-minute walk test, and COPD assessment test.
Follow-up visits as per clinical routine
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Rickard Zeijlon, Sara Zooq, Angela Poller...
https://pubmed.ncbi.nlm.nih.gov/42055737/Sahlgrenska University Hospital
Lead Sponsor
